-
May 24, 2022 5 Psychedelic Books Our Staff LovesMembers of the Psychedelic Spotlight team share their favorite psychedelic books that explore our favorite...
-
May 21, 2022 My First Frightening Trip…Into Feature FilmmakingThe producer and director of our flagship video series "Spotlight in Focus" writes about the...
-
May 20, 2022 CATALYST Summit: 3 Psychedelic Speakers to Catch This WeekendEven if you can't be there in person, it's not too late to get a...
-
May 20, 2022 Psychedelic Business Spotlight – May 20This week in psychedelic business news: Another psychedelic merger; an Optimi Health acquisition; and good...
-
May 19, 2022 Psychedelic Capitalism Takes a Trip to DavosFrom May 21-26, for the first time, the Davos Forum will feature The House of...
-
May 18, 2022 COVID-19 on Mushrooms: A Psilocybin Trip ReportI finally caught the bug, and after a mild bout with the Coronavirus, I ate...
-
May 17, 2022 Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisOur resident psychedelic investor explains a handful of important metrics to study when analyzing and...
-
May 16, 2022 A Brief History of MDMA: From the CIA to Raves to Psychedelic TherapyThe history of MDMA is fascinating, and it is still being written.
-
May 13, 2022 Psychedelic Business Spotlight – May 13This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the...
-
May 11, 2022 MindMed’s Phase 2 LSD Trial Treating Anxiety Was a SuccessResearchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
